)
)
Egetis Therapeutics Investor Relations Material
Latest events
Q3 2024
Egetis Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Egetis Therapeutics
Access all reports
Egetis Therapeutics develops and markets drugs for the treatment of rare and serious diseases in the orphan drug segment. Its main drug candidates currently include Aladote, a drug that reduces the risk of acute liver injury associated with acetaminophen/paracetamol poisoning and is being developed in phase IIb/III clinical trials; and Emcitate, a drug for the treatment of MCT8 deficiency (a rare inborn error of thyroid hormone signaling).
Key slides for Egetis Therapeutics
Corporate Presentation
Egetis Therapeutics
Corporate Presentation
Egetis Therapeutics
Latest articles
)
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
)
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
)
Mips: The Gore-Tex of Brain Protection
How Mips turned a critical safety flaw into a global success, redefining helmet protection with its technology and ingredient brand business model.
24 Jan 2025
Ticker symbol
EGTX
Country
🇸🇪 Sweden